GELSTAT CORP
GSAC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GSAC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GSAC
Gelstat Corp is a consumer health care company focused on developing and marketing over-the-counter (OTC) and non-prescription products, with its first product being a patented homeopathic migraine treatment.
Key risk: Cash shortage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.1M
Cash Runway
—
Lead Asset
gelstat migraine (Approved)
Next Catalyst
—
Financial data as of Dec 31, 2007.
Tracking 1 pipeline candidate for GELSTAT CORP.
Gelstat Corp is a consumer health care company focused on developing and marketing over-the-counter (OTC) and non-prescription products, with its first product being a patented homeopathic migraine treatment.
- Gelstat Corp is a consumer health care company dedicated to cost-effective development and marketing of OTC and non-prescription products [sec_mda · as of 2012-10-22].
- The company's first product is Gelstat® Migraine, a patented OTC homeopathic drug for acute treatment of migraine and migraine-like headaches [sec_mda · as of 2012-10-22].
- As of the filing date of a report, the company had approximately $5,000 cash and needs to raise additional capital to continue operations [sec_mda · as of 2012-10-19].
- The company's ability to continue operations is contingent on increasing revenues, attaining profitable operations, or raising additional capital [sec_mda · as of 2012-10-22].
- Gelstat has a preclinical pipeline candidate, 'gelstat sleep,' an orally dispersible tablet for sleep aid, facing 18 competitors in various phases [pipeline].
What works
- Gelstat has a patented OTC homeopathic product, Gelstat® Migraine, already on the market, providing a first-line acute treatment option [sec_mda · as of 2012-10-22].
- The company is expanding its pipeline with a preclinical sleep aid candidate, 'gelstat sleep,' in a large market with multiple competitors [pipeline].
What to weigh
- The company had only approximately $5,000 cash as of a recent filing, indicating severe liquidity constraints [sec_mda · as of 2012-10-19].
- Gelstat's ability to continue operations is uncertain and depends on raising additional capital, increasing revenues, or achieving profitability [sec_mda · as of 2012-10-22].
- The pipeline candidate 'gelstat sleep' is only in preclinical stage, facing 18 competitors, many in Phase 2 or Phase 3 trials [pipeline].
From the filings
Quoted directly from source documents.
Gelstat's first product is a patented OTC homeopathic migraine treatment.
“The Company's first product is "Gelstat® Migraine", a patented OTC homeopathic drug intended for use as a first-line, acute treatment for migraine and migraine-like headaches.”
SEC MD&A · October 22, 2012
The company had very low cash and needs additional capital.
“As of the date of filing this Report, the Company had approximately $5,000 cash. The Company needs to raise additional capital to continue operations.”
SEC MD&A · October 19, 2012
Gelstat's pipeline includes a preclinical sleep aid.
“Pipeline Candidate: gelstat sleep Indication: sleep aid Phase: Preclinical Delivery Vector: orally dispersible tablet”
Risks & what to watch (3)›
Key risks
- Cash shortage — Approximately $5,000 cash as of filing; needs to raise capital to continue operations [sec_mda · as of 2012-10-19].
- Going concern uncertainty — Operations depend on increasing revenues, achieving profitability, or raising additional capital [sec_mda · as of 2012-10-22].
- Early-stage pipeline — Only preclinical candidate 'gelstat sleep' faces 18 competitors, many in later-stage trials [pipeline].
What to watch
- Ability to raise additional capital to fund operations and development [sec_mda · as of 2012-10-19].
- Progress of 'gelstat sleep' from preclinical to clinical stages [pipeline].
- Revenue generation from Gelstat® Migraine and potential market expansion [sec_mda · as of 2012-10-22].
Sources: Pipeline · SEC MD&A · Generated August 3, 2026 · How we verify sources →
Run GELSTAT CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GELSTAT CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$162K
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for GELSTAT CORP?
Gelstat Corp is a consumer health care company focused on developing and marketing over-the-counter (OTC) and non-prescription products, with its first product being a patented homeopathic migraine treatment.
What is GELSTAT CORP's lead drug candidate?
GELSTAT CORP's most advanced tracked candidate is gelstat migraine (Approved) for acute relief from migraine and migraine-like headaches.
Who is the CEO of GELSTAT CORP?
Mr. Javier G. Acosta is the chief executive officer of GELSTAT CORP (GSAC).
Where is GELSTAT CORP headquartered?
GELSTAT CORP (GSAC) is headquartered in Palm City, FL, United States.
What therapeutic areas does GELSTAT CORP focus on?
GELSTAT CORP develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.